MX2009003082A - Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl. - Google Patents
Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl.Info
- Publication number
- MX2009003082A MX2009003082A MX2009003082A MX2009003082A MX2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A MX 2009003082 A MX2009003082 A MX 2009003082A
- Authority
- MX
- Mexico
- Prior art keywords
- leukemia
- tyrosine kinase
- abl tyrosine
- cmin
- bcr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ecology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona un método para el tratamiento de leucemia positiva para Filadelfia (Ph+), tal como leucemia linfoblástica aguda positiva para el cromosoma Filadelfia (Ph+ ALL) o leucemia mieloide crónica (CML), en una población de pacientes humanos, el cual comprende los pasos de: (a) administrar una cantidad fija previamente determinada de un inhibidor de cinasa de tirosina Bcr-Abl, tal como imatinib, o una sal farmacéuticamente aceptable del mismo, a los pacientes humanos que sufran de una leucemia Ph+, (b) recolectar cuando menos una muestra de sangre de estos pacientes, (c) determinar el nivel en plasma de artesa (Cmin) del inhibidor de cinasa de tirosina Bcr-Abl, o de un metabolito del mismo, así como los índices de respuesta molecular mayor, (d) evaluar un potencial de discriminación de la concentraciones en plasma de artesa para la respuesta molecular mayor, e identificar un umbral de Cmin para la sensibilidad y especifidad óptimas, y (e) ajustar la dosis del inhibidor de la cinasa de tirosina Bcr-Abl, o una sal farmacéuticamente aceptable del mismo, aplicada a los pacientes individuales a partir de la población de pacientes mencionada, y opcionalmente, a pacientes futuros que sufran de una leucemia Ph+ de una manera en que se alcance una Cmin en cada paciente individual igual o mayor que el umbral de Cmin obtenido de acuerdo con el paso (d).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82662206P | 2006-09-22 | 2006-09-22 | |
| US82827806P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/078978 WO2008036792A2 (en) | 2006-09-22 | 2007-09-20 | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003082A true MX2009003082A (es) | 2009-04-01 |
Family
ID=39092883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003082A MX2009003082A (es) | 2006-09-22 | 2007-09-20 | Metodo para optimizar el tratamiento de leucemia positiva para filadelfia, con inhibidores de cinasa de tirosina abl. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090281113A1 (es) |
| EP (2) | EP2251042A3 (es) |
| JP (1) | JP5735742B2 (es) |
| KR (1) | KR20090065512A (es) |
| AT (1) | ATE495761T1 (es) |
| AU (1) | AU2007299764B2 (es) |
| BR (1) | BRPI0717099A2 (es) |
| CA (1) | CA2662977A1 (es) |
| CL (1) | CL2007002725A1 (es) |
| CY (1) | CY1111356T1 (es) |
| DE (1) | DE602007012122D1 (es) |
| DK (1) | DK2068938T3 (es) |
| HK (1) | HK1133194A1 (es) |
| HR (1) | HRP20110250T1 (es) |
| IL (1) | IL197296A (es) |
| MA (1) | MA30786B1 (es) |
| MX (1) | MX2009003082A (es) |
| NO (1) | NO20091490L (es) |
| NZ (1) | NZ575113A (es) |
| PL (1) | PL2068938T3 (es) |
| PT (1) | PT2068938E (es) |
| TN (1) | TN2009000094A1 (es) |
| TW (1) | TWI398251B (es) |
| WO (1) | WO2008036792A2 (es) |
| ZA (1) | ZA200901220B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101579993B1 (ko) | 2008-01-23 | 2015-12-23 | 노파르티스 아게 | 이마티닙을 이용한 티로신 키나제 수용체 ｋｉｔ에 의해 매개되는 증식성 질환의 치료를 최적화하는 방법 |
| JP2012510470A (ja) * | 2008-12-01 | 2012-05-10 | ノバルティス アーゲー | メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法 |
| US20110046919A1 (en) | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
| FR2943418A1 (fr) * | 2009-03-17 | 2010-09-24 | Centre Nat Rech Scient | Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications |
| WO2015076213A1 (ja) * | 2013-11-22 | 2015-05-28 | 独立行政法人国立成育医療研究センター | 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ－ｐｄｇｆｒｂ |
| WO2017007547A1 (en) | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
| CN114994213A (zh) * | 2022-06-28 | 2022-09-02 | 北京赛诺浦生物技术有限公司 | 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| US20050164196A1 (en) * | 2002-04-17 | 2005-07-28 | Dressman Marlene M. | Methods to predict patient responsiveness to tyrosine kinase inhibitors |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| ES2396135T3 (es) | 2004-06-10 | 2013-02-19 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
-
2007
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 EP EP10171365A patent/EP2251042A3/en not_active Withdrawn
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 EP EP07842842A patent/EP2068938B1/en active Active
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en active Application Filing
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Application Discontinuation
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
-
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
- 2009-12-04 HK HK09111401.1A patent/HK1133194A1/xx not_active IP Right Cessation
-
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
- 2011-04-07 HR HR20110250T patent/HRP20110250T1/hr unknown
-
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000094A1 (en) | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors | |
| Cappuzzo et al. | Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) | |
| EA201190042A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| TW200512298A (en) | Method of diagnosing breast cancer | |
| JP2015504847A5 (es) | ||
| WO2003103676A3 (en) | METHOD FOR TREATING CANCER USING KINASE INHIBITORS | |
| Wang et al. | Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| WO2010066891A3 (en) | Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients | |
| RU2010101634A (ru) | Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi | |
| BRPI0518795A2 (pt) | mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio | |
| RU2017143182A (ru) | Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| Abbasian et al. | Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance. | |
| Wajid et al. | EARLY MOLECULAR RESPONSE WITH IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA AND ITS ASSOCIATION WITH BASELINE WHITE BLOOD CELL COUNT AND SPLEEN SIZE: Early Molecular Response With Imatinib Therapy | |
| US8697702B2 (en) | Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| RU2011122721A (ru) | Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl | |
| TW200507828A (en) | Method for treatment of chemotherapy-induced diarrhea | |
| RU2483732C2 (ru) | СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ | |
| Chen et al. | The Role of Abnormal Expression of Clock Gene DBP Mediated by Gut Microbiota Dysbiosis in Cognitive Dysfunction in ESRD and the Underlying Mechanism: PO2485 | |
| DeLalio et al. | Circadian Cycle Exaggerates Sympathoexcitatory Responses to Activation of Chemosensitive Renal Sensory Nerves: PO2486 | |
| Holfelder et al. | The MTORC1-AHR pathway sustains translation and autophagy in tumours under tryptophan stress | |
| CN114053409A (zh) | 整合素蛋白作为标志物在制备治疗结直肠癌药物中的应用 | |
| WO2001045690A3 (en) | Use of bvdu for inhibiting the growth of hyperproliferative cells | |
| Mok et al. | THU0186 Anti-Drug Antibodies, Drug Levels and Clinical Efficacy of the Anti-TNF Biologics in Rheumatic Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |